Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03803787
Other study ID # CI/910/17
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 1, 2018
Est. completion date December 1, 2024

Study information

Verified date November 2023
Source Instituto Nacional de Cancerologia de Mexico
Contact Oscar Arrieta, MD MSc
Phone 015556280400
Email ogarrieta@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This randomized clinical study aims to assess whether prophylactic treatment with inhaled steroids in patients with locally advanced or concomitantly treated non-small cell lung carcinoma who are candidates for combination treatment with QT/RT or IMT + QT/RT. The main questions it aims to answer are: Whether prophylactic treatment decreases the severity of NPR on CTCAE v4.0 and RTOG scales. Whether inhaled steroid use modifies the response to radiation therapy treatment compared to patients who do not receive prophylactic inhaled steroids.


Description:

Clinical evaluation The following BASELINE data shall be taken prior to radiation therapy: Demographic, clinical, laboratory, and imaging data will be obtained from medical history and electronic records. The patient will be instructed to perform the PFRs and tests of lung function. Two EORTC, QLQ-C30, and QLQ LC13 quality of life questionnaires and three respiratory symptom questionnaires (St. George, dyspnea scale, and modified BORG) will be performed on the same day of lung function tests. Additionally; blood samples will be taken for the evaluation of inflammatory mediators at the following times: BASAL (before RT), and every six weeks up to 48 weeks post-RT. INTERVENTION GROUP 1. Prior to the onset of RT, the patient will be sorted to receive the control rather than experimental intervention (QT/RT or IMT + QT/RT) and a logbook to record adherence to treatment. 2. An IDM device shall be granted per month, containing the number of doses corresponding to 30 days. The record in the database of the day of the first session of RT will be taken to quantify the number of days of use of the drug and grant the next device per 30 days until the end of the study. 3. The patient will be instructed on the use of the device inhaled with the spacer chamber in the clinic Pulmonology consultation, alarm data and indications of the use of the drug will be given in writing, and knowledge will be reinforced at each visit. 4. The patient will be granted the drug use log where the patient will place the date and time of use of the drug to assess adherence to treatment


Recruitment information / eligibility

Status Recruiting
Enrollment 72
Est. completion date December 1, 2024
Est. primary completion date September 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients with non-small cell lung cancer (NSCLC) with unresectable locally advanced or metastatic disease (IIIA, IIIB or IV) of the classification tumor node, metastasis (TNM) of malignant lung tumors, 7th edition. - NSCLC patients candidates for concomitant treatment (chemotherapy plus radiotherapy or target therapy plus radiotherapy). - Evidence of measurable disease - Eastern Cooperative Oncology Group (ECOG) performance status = 2, Karnofsky 70-100. - Life expectancy of > 4 months at the time of screening - Patients with the ability to comply with the study and follow-up procedures. - Patients with previous surgery less than four weeks. - Must be willing and able to give signed informed consent and, in the opinion of the Investigator, to comply with the protocol tests and procedures. Exclusion Criteria: - Unstable systemic disease: active infection, heart, liver, kidney or metabolic disease; including uncontrolled chronic lung disease. - Patients treated with systemic or inhaled corticosteroids. - Patients of reproductive age without a family planning method, pregnant or lactating. - Previous diagnosis of Pneumonitis with toxicity grade = 2 by CTCAE v4.0 or RTOG scale. - Patients with disease progression. - Inspiratory flow < 90 liters / min. - Discontinue of Treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Inhaled budesonide
Patients will use inhaled budesonide (Numark) with space chamber at 400 mcg given twice daily initiating after the first dose of RT and continuing until pneumonitis development or 12 months completed.

Locations

Country Name City State
Mexico Instituto Nacional de Cancerologia Mexico City
Mexico Instituto Nacional de Enfermedades Respiratorias Mexico City

Sponsors (2)

Lead Sponsor Collaborator
Instituto Nacional de Cancerologia de Mexico Instituto Nacional de Enfermedades Respiratorias

Country where clinical trial is conducted

Mexico, 

References & Publications (11)

Arrieta O, Guzman-de Alba E, Alba-Lopez LF, Acosta-Espinoza A, Alatorre-Alexander J, Alexander-Meza JF, Allende-Perez SR, Alvarado-Aguilar S, Araujo-Navarrete ME, Argote-Greene LM, Aquino-Mendoza CA, Astorga-Ramos AM, Austudillo-de la Vega H, Aviles-Salas — View Citation

Bledsoe TJ, Nath SK, Decker RH. Radiation Pneumonitis. Clin Chest Med. 2017 Jun;38(2):201-208. doi: 10.1016/j.ccm.2016.12.004. Epub 2017 Mar 1. — View Citation

Daley-Yates PT. Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 2015 Sep;80(3):372-80. doi: 10.1111/bcp.12637. Epub 2015 May 28. — View Citation

Ding NH, Li JJ, Sun LQ. Molecular mechanisms and treatment of radiation-induced lung fibrosis. Curr Drug Targets. 2013 Oct;14(11):1347-56. doi: 10.2174/13894501113149990198. — View Citation

Henkenberens C, Janssen S, Lavae-Mokhtari M, Leni K, Meyer A, Christiansen H, Bremer M, Dickgreber N. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-cent — View Citation

Kim S, Oh IJ, Park SY, Song JH, Seon HJ, Kim YH, Yoon SH, Yu JY, Lee BR, Kim KS, Kim YC. Corticosteroid therapy against treatment-related pulmonary toxicities in patients with lung cancer. J Thorac Dis. 2014 Sep;6(9):1209-17. doi: 10.3978/j.issn.2072-1439 — View Citation

Leach C, Colice GL, Luskin A. Particle size of inhaled corticosteroids: does it matter? J Allergy Clin Immunol. 2009 Dec;124(6 Suppl):S88-93. doi: 10.1016/j.jaci.2009.09.050. — View Citation

Simone CB 2nd. Thoracic Radiation Normal Tissue Injury. Semin Radiat Oncol. 2017 Oct;27(4):370-377. doi: 10.1016/j.semradonc.2017.04.009. — View Citation

Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inop — View Citation

Vallard A, Rancoule C, Le Floch H, Guy JB, Espenel S, Le Pechoux C, Deutsch E, Magne N, Chargari C. [Medical prevention and treatment of radiation-induced pulmonary complications]. Cancer Radiother. 2017 Aug;21(5):411-423. doi: 10.1016/j.canrad.2017.03.00 — View Citation

Williams JP, Johnston CJ, Finkelstein JN. Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets. 2010 Nov;11(11):1386-94. doi: 10.2174/1389450111009011386. — View Citation

* Note: There are 11 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Pneumonitis graded by the Common terminology criteria for adverse event v4.0. (CTCAE v4.0). Current score for radiation pneumonitis according to symptoms and radiographic changes. Grade 0: No changes, Grade 1: Asymptomatic or mild respiratory symptoms, Grade 2: Moderate respiratory symptoms of pneumonitis (a severe cough) and radiographic changes (radiographic patches), Grade 3: Severe respiratory symptoms of pneumonitis, dense radiographic changes. Grade 4: Symptoms of acute respiratory failure requiring assisted ventilation or continuous oxygen. Grade 5: Death directly related to late effects of radiotherapy. from the beginning of radiotherapy up to 1 year after the 1st session.
Primary Pneumonitis graded by the Radiation Therapy Oncology Group score (RTOG) Current score for radiation pneumonitis according to symptoms and radiographic changes. Grade 0: No changes, Grade 1: Asymptomatic, only radiological or tomographic findings, Grade 2: Symptomatic, does not interfere with daily activities, Grade 3: Symptomatic, interferes with daily activities, requires supplemental oxygen. Grade 4: Threatens life, needing ventilator support. Grade 5: Severe pneumonitis with fatal outcome. from the beginning of radiotherapy up to 1 year after the 1st session.
Secondary Lung cancer-associated symptoms assessment Symptoms are evaluated with the supplementary lung cancer-specific questionnaire of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (validated Mexican-Spanish version).
It comprises 13 questions related to the assessment of dyspnoea, pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a higher level of symptoms.
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Treatment-related side effects in lung cancer Symptoms are evaluated with the supplementary lung cancer-specific questionnaire of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (validated Mexican-Spanish version).
It comprises 13 questions related to the assessment of dyspnoea, pain, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a higher level of side-effects.
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Cognitive functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire The cognitive functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to the assessment of short and long-term memory. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that scores range from 0 to 100. A higher scale score represents a healthy level of functioning.
before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Emotional Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire The Emotional Functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises four questions related to the assessment of depression, anxiety, irritability, and stress. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning.
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment
Secondary Physical functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire The Physical functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises five questions related to self-sufficiency activities (eating, walking, laying in bed or completing simple chores). The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning.
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Role Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire The Role functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to daily activities (work and hobbies limitation). The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning.
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Social Functioning evaluated by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire The Social Functioning is evaluated using the validated Mexican-Spanish version of the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaires.
It comprises two questions related to family life and social activities. The items scale ranges from 1 (Not at all) to 4 (Very much). The average of the items that contribute to the scale (raw score) is estimated and transformed so that the scores range from 0 to 100. A higher scale score represents a represents a healthy level of functioning.
before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Respiratory symptoms evaluation using St. George respiratory questionnaire Respiratory symptoms are evaluated using the St. George respiratory questionnaire validated to Mexican-Spanish version. It is a disease-specific instrument designed to measure the impact on overall health, daily life, and perceived well-being in patients with airways disease. Scores range from 0 to 100, with higher scores indicating more limitations. before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Dyspnea assessment by the Borg Scale Dyspnea Index (BSDI) A system used to document the severity of the patient's shortness of breath using numbers anchored with verbal descriptions. This scale asks the patient to rate the dyspnea. It starts at number 0 where the breathing is causing no difficulty at all and progresses through to number 10 where the breathing difficulty is maximal. before the start Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Pulmonary function evaluation using spirometry test Spirometry measures the inhaled and exhaled air volume as a function of time using a forced expiratory maneuver. before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment
Secondary Pulmonary function evaluation using diffusion lung capacity of carbon monoxide measurement (DLCO). Diffusion lung capacity of carbon monoxide (DLCO) test measures the conductance of gas transfer from inspired gas to the red blood cells. before the start of Radiotherapy and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Airway inflammatory response evaluation using the fraction of exhaled nitric oxide measurement (FeNO) Nitric oxide concentration detected in the exhaled gas by chemiluminescence reported as particles per million. before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
Secondary Pulmonary function evaluation using Impulse oscillometry test (IOS) Impulse oscillometry provides a rapid, noninvasive measure of airway impedance during normal tidal breathing. before the start of Radiotherapy, and at 6, 12, 24 and 48-weeks post-treatment.
See also
  Status Clinical Trial Phase
Recruiting NCT02490319 - Study on the Biological Prediction Models of Radiation Pneumonitis
Completed NCT03796364 - Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis Phase 2
Not yet recruiting NCT04632342 - Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients Phase 2
Recruiting NCT05365802 - FAPI PET for Lung Fibrosis Early Phase 1
Completed NCT01754909 - Mitigation of Radiation Pneumonitis and Fibrosis Phase 2
Recruiting NCT05189496 - Hyperbaric Oxygen in the Prevention of Radiation Pneumonitis N/A
Completed NCT01745484 - Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation N/A
Enrolling by invitation NCT02809456 - Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients Phase 2
Recruiting NCT00155909 - Risk Factors of Radiation Pneumonitis N/A
Recruiting NCT06069115 - Radiotherapy Exposed Lung Injury: Effect on Functioning - Cohort
Not yet recruiting NCT02296281 - Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury Phase 2
Completed NCT04863027 - Use of Dual Energy Computed Tomography in Thoracic Radiotherapy Planning.
Completed NCT03462524 - Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology N/A
Recruiting NCT05448703 - A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis
Recruiting NCT06079931 - The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia Phase 2
Recruiting NCT04676828 - Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer N/A
Recruiting NCT02735746 - Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis